Starling
AI-driven home urine diagnostics for early disease detection and monitoring.
AI-driven home urine diagnostics for early disease detection and monitoring.
Starling, founded with the mission to revolutionize home healthcare, focuses on AI-driven urine diagnostics for early disease detection and monitoring. Their core product is a remote patient monitoring platform that integrates seamlessly into users' bathroom routines. Utilizing mass spectroscopy-based sensors, the platform detects changes in urine to prevent hospitalizations from conditions such as recurrent UTIs, BPH exacerbations, and diabetes. Starling aims to enhance patient outcomes while generating new revenue streams for clinician partners through remote patient monitoring reimbursements.
Notable figures associated with Starling include leading healthcare professionals and AI experts who have contributed to its innovative approach. The company has secured significant investment from key players in the health tech industry, underscoring its potential impact. Starling's achievements include successful pilot programs demonstrating reduced hospital admission rates and improved chronic condition management. Overall, Starling is making a substantial impact on the healthcare landscape by providing a practical, at-home solution for continuous health monitoring.
Companies similar to Starling include VitalFlo, BioIntelliSense, Bright Uro and Zeit Medical.
Starling was founded in 2019.
Starling's headquarters is located in Houston, TX, US.
Starling's most recent funding round was for $3.4M (USD) in January 2023.
As of Jan 27, 2023, Starling has disclosed funding of $4.2M (USD). Undisclosed round amounts are excluded.
Starling has 5 employees as of Feb 21, 2024.
Zeit Medical
zeitmedical.com
